Follow-up duration and tuberculosis do not modify the comparative safety of JAK inhibitors in ulcerative colitis. Meyer A, Amiot A. J Crohns Colitis 2026;20:jjag142.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Meyer A, Amiot A. Follow-up duration and tuberculosis do not modify the comparative safety of JAK inhibitors in ulcerative colitis. J Crohns Colitis 2026;20:jjag142.
PMID: 42758047